CYTOF (Altamira Therapeutics) Short-Term Debt: $0.45 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Altamira Therapeutics Short-Term Debt?

Altamira Therapeutics CYTOF -25.21% Short-Term Debt is $0.45 Mil as of Jun. 2025. The stock has 4 warning signs investors should review.

Altamira Therapeutics's Short-Term Debt for the quarter that ended in Jun. 2025 was $0.45 Mil.

Altamira Therapeutics's quarterly Short-Term Debt stayed the same from Jun. 2024 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Jun. 2025 ($0.45 Mil).

Altamira Therapeutics's annual Short-Term Debt declined from Dec. 2022 ($6.35 Mil) to Dec. 2023 ($0.00 Mil) but then stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

Altamira Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Altamira Therapeutics Short-Term Debt Related Terms

Altamira Therapeutics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Altamira Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altamira Therapeutics Short-Term Debt Chart

Altamira Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.60 0.00 6.35 0.00 0.00

Altamira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.37 0.00 0.00 0.00 0.45
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.45 Mil mean?
Altamira Therapeutics (CYTOF) has a Short-Term Debt of $0.45 Mil as of Jun. 2025.
Is Altamira Therapeutics' Short-Term Debt too high?
Altamira Therapeutics' current Short-Term Debt is $0.45 Mil.
How does Altamira Therapeutics' Short-Term Debt compare to CARM and PTIX?
Altamira Therapeutics' Short-Term Debt of $0.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Altamira Therapeutics's current Short-Term Debt is $0.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altamira Therapeutics stock overvalued right now?
Altamira Therapeutics (CYTOF) has a current Short-Term Debt of $0.45 Mil. The current Short-Term Debt is $0.45 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Altamira Therapeutics (CYTOF), the current Short-Term Debt is $0.45 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Altamira Therapeutics Business Description

Address 2 Church Street, Clarendon House, Hamilton, BMU, HM11
Altamira Therapeutics Ltd is developing and supplying peptide-based nanoparticles for safe and effective RNA delivery to extrahepatic tissues (xPhore platform). The Company is offering biopharmaceutical companies access to its technology for use with their own RNA molecules under collaboration and licensing agreements. The xPhore platform is suitable for various RNA modalities - OligoPhore for oligonucleotides, SemaPhore for mRNA, CycloPhore for circRNA - as well as for DNA (GenePhore). In addition, Altamira Therapeutics is pursuing two proprietary flagship development programs using OligoPhore: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Geographically, the companies operates in United Staes and Switzerland.